Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China: Lejia Sun, Wenmo Hu, Meixi Liu, Yang Chen, Bao Jin, Haifeng Xu, Shunda Du, Yiyao Xu, Haitao Zhao, Xin Lu, Xinting Sang, Shouxian Zhong, Huayu Yang, Yilei Mao; Cancer Res Treat. 2020;52(4):1199-1210. Published online July 21, 2020; DOI: https://doi.org/10.4143/crt.2020.303

Purpose
The systemic inflammation response index (SIRI) has been reported to have prognostic ability in various solid tumors but has not been studied in gallbladder cancer (GBC). We aimed to determine its prognostic value in GBC.
Materials and Methods
From 2003 to 2017, patients with confirmed GBC were recruited. To determine the SIRI’s optimal cutoff value, a time-dependent receiver operating characteristic curve was applied. Univariate and multivariate Cox analyses were performed for the recognition of significant factors. Then the cohort was randomly divided into the training and the validation set. A nomogram was constructed using the SIRI and other selected indicators in the training set, and compared with the TNM staging system. C-index, calibration plots, and decision curve analysis were performed to assess the nomogram’s clinical utility.
Results
One hundred twenty-four patients were included. The SIRI’s optimal cutoff value divided patients into high (≥ 0.89) and low SIRI (< 0.89) groups. Kaplan-Meier curves according to SIRI levels were significantly different (p < 0.001). The high SIRI group tended to stay longer in hospital and lost more blood during surgery. SIRI, body mass index, weight loss, carbohydrate antigen 19-9, radical surgery, and TNM stage were combined to generate a nomogram (C-index, 0.821 in the training cohort, 0.828 in the validation cohort) that was significantly superior to the TNM staging system both in the training (C-index, 0.655) and validation cohort (C-index, 0.649).
Conclusion
The SIRI is an independent predictor of prognosis in GBC. A nomogram based on the SIRI may help physicians to precisely stratify patients and implement individualized treatment.

Citations

Citations to this article as recorded by

Combining systemic inflammatory response index and albumin fibrinogen ratio to predict early serious complications and prognosis after resectable gastric cancer
Jing-Yao Ren, Da Wang, Li-Hui Zhu, Shuo Liu, Miao Yu, Hui Cai
World Journal of Gastrointestinal Oncology.2024; 16(3): 732. CrossRef
Association of Systemic Inflammation Response Index with Short-Term All-Cause Mortality in Decompensated Liver Cirrhosis Patients
Jin Cheng, Honglei Ju, Guixiang Wang, Chiyi He, Wei Wang
Journal of Inflammation Research.2024; Volume 17: 8985. CrossRef
The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma
Tian Wang, Duo Zhang, Di Tang, Yu Heng, Li-ming Lu, Lei Tao
Journal of Cancer Research and Clinical Oncology.2023; 149(9): 5627. CrossRef
Preoperative Fibrinogen Albumin Ratio is an Effective Biomarker for Prognostic Evaluation of Gallbladder Carcinoma After Radical Resection: A 10-Year Retrospective Study at a Single Center
Qi Li, Jian Zhang, Qi Gao, Jialu Fu, Mengke Li, Hengchao Liu, Chen Chen, Dong Zhang, Zhimin Geng
Journal of Inflammation Research.2023; Volume 16: 677. CrossRef
Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation
Songping Cui, Shuang Cao, Qing Chen, Qiang He, Ren Lang
Frontiers in Immunology.2023;[Epub] CrossRef
Assessment of aggregate index of systemic inflammation and systemic inflammatory response index in dry age-related macular degeneration: a retrospective study
Naif S. Sannan
Frontiers in Medicine.2023;[Epub] CrossRef
Value of preoperative systemic inflammatory response index and prognostic nutritional index in predicting prognosis of patients with superficial esophageal squamous cell carcinoma
Jing Wang, Xue-Li Ding, Zi-Bin Tian
World Chinese Journal of Digestology.2023; 31(9): 369. CrossRef
The Prognostic Value and Potential Mechanism of Tumor-Nutrition-Inflammation Index and Genes in Patients with Advanced Lung Cancer
Huan Wang, Yuting Shi, Yueli Shi, Mengqing Cao, Long Zhang, Yuan Wu, Yun Xu, Kai Wang, Xianwu Weng, Bing Niu
International Journal of Clinical Practice.2023; 2023: 1. CrossRef
The Potential Value of Systemic Inflammation Response Index on Delirium After Hip Arthroplasty Surgery in Older Patients: A Retrospective Study
Wenbin Lu, Shengwei Lin, Cheng Wang, Peipei Jin, Jinjun Bian
International Journal of General Medicine.2023; Volume 16: 5355. CrossRef
Systemic Inflammation Response Index (SIRI) Independently Predicts Survival in Advanced Lung Adenocarcinoma Patients Treated with First-Generation EGFR-TKIs
Shun Jiang, Sisi Wang, Qianqian Wang, Chao Deng, Yuhua Feng, Fang Ma, Jin'an Ma, Xianling Liu, Chunhong Hu, Tao Hou
Cancer Management and Research.2021; Volume 13: 1315. CrossRef
The Prognostic Value of Preoperative Systemic Inflammatory Response Index (SIRI) in Patients With High-Grade Glioma and the Establishment of a Nomogram
Qian He, Longhao Li, Qinglan Ren
Frontiers in Oncology.2021;[Epub] CrossRef
Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection
Yu-Jia Shen, Li-Qiang Qian, Zheng-Ping Ding, Qing-Quan Luo, Heng Zhao, Wu-Yan Xia, Yuan-Yuan Fu, Wen Feng, Qin Zhang, Wen Yu, Xu-Wei Cai, Xiao-Long Fu
Frontiers in Oncology.2021;[Epub] CrossRef

8,886 View
114 Download
26 Web of Science
12 Crossref

Trends in Gallbladder Cancer Incidence and Survival in Korea: Youngjun Wi, Hyeongtaek Woo, Young-Joo Won, Jin-Young Jang, Aesun Shin; Cancer Res Treat. 2018;50(4):1444-1451. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.279

Abstract PDF Supplementary Material PubReader ePub

Purpose
The current study was undertaken to examine the trend in gallbladder cancer (GBC) incidence and survival in Korea.
Materials and Methods
GBC incidence data by histologic typewere obtained from the Korea Central Cancer Registry. Age-standardized incidence rates were calculated using the mid-year Korean population of 2000 as a standard population, and a joinpoint regression model was used to calculate the annual percent change (APC) in incidence rates. Incidence by Surveillance, Epidemiology and End Results (SEER) summary stage and by geographical areas and female-to-male incidence rate ratios was also described.
Results
The number of new GBC cases increased between 1999 and 2013. Nevertheless, the agestandardized incidence rate decreased by 0.5% per year in men (p < 0.01), whereas the incidence rate in women did not change significantly over the same period (APC, –0.2; p=0.6). The most common histologic type was adenocarcinoma in both sexes. Based on the SEER stage, the distant stage was the most frequent stage (41%), followed by the regional stage (37%). Ulsan (4.31/100,000 for men and 4.09/100,000 forwomen in 2009- 2013) and Gyeongsangnam-do (4.15/100,000 for men and 3.54/100,000 for women) showed the highest GBC incidence, whereas the lowest incidence was observed in Seoul and Gyeonggi-do. There were no significant sex differences in the incidence of GBC (femaleto-male incidence rate ratio, 0.96).
Conclusion
The overall incidence of GBC in Korea did not change significantly over the 15-year period. Incidence for men and women was similar. However, geographical variation was found.

Citations

Citations to this article as recorded by

Viscum album, as alternative and bridge to palliative chemotherapy in recurrent gallbladder cancer following laparoscopic radical cholecystectomy: a case report
Joonggyeong Shin, Eunsang Yim, Chang Moo Kang
Korean Journal of Clinical Oncology.2024; 19(2): 88. CrossRef
Association of female reproductive and hormonal factors with gallbladder cancer risk in Asia: A pooled analysis of the Asia Cohort Consortium
Aesun Shin, Sooyoung Cho, Sarah Krull Abe, Md Rashedul Islam, Md Shafiur Rahman, Eiko Saito, Sayada Zartasha Kazmi, Ryoko Katagiri, Melissa Merritt, Ji‐Yeob Choi, Xiao‐Ou Shu, Norie Sawada, Akiko Tamakoshi, Woon‐Puay Koh, Ritsu Sakata, Atsushi Hozawa, Jeo
International Journal of Cancer.2024; 155(2): 240. CrossRef
Establishment of a chronic biliary disease mouse model with cholecystoduodenal anastomosis for intestinal microbiome preservation
Yunseon Jang, Jung Yeon Kim, Song Yeon Han, Arum Park, So Jeong Baek, Gyurim Lee, Jihee Kang, Hyewon Ryu, Seok-Hwan Kim
World Journal of Gastroenterology.2024; 30(46): 4937. CrossRef
Lessons learnt from 1300 consecutive gallbladder cancer surgeries: Evolving role of peri-operative chemotherapy in the treatment paradigm
Shraddha Patkar, Swapnil Patel, Amit Gupta, Vikas Ostwal, Anant Ramaswamy, Nitin Shetty, Mahesh Goel
European Journal of Surgical Oncology.2023; 49(10): 107035. CrossRef
Clinicopathologic significance of the delta-like ligand 4, vascular endothelial growth factor, and hypoxia-inducible factor-2α in gallbladder cancer
Sujin Park, Junsik Kim, Woncheol Jang, Kyoung-Mee Kim, Kee-Taek Jang
Journal of Pathology and Translational Medicine.2023; 57(2): 113. CrossRef
Radical surgery for stage IV gallbladder cancers: Treatment strategies in patients with limited metastatic burden
Shraddha Patkar, Swapnil Patel, Mufaddal Kazi, Mahesh Goel
Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(2): 180. CrossRef
EGFR-targeted fluorescent imaging using the da Vinci® Firefly™ camera for gallbladder cancer
Jung Ha Choi, Chang Moo Kang, Jeong Youp Park
World Journal of Surgical Oncology.2022;[Epub] CrossRef
Publication Trends of Research on Gallbladder Cancer During 2001–2021: A 20-Year Bibliometric Analysis
Wentao Sun, Wenze Wan, Zhihui Gao, Tao Suo, Sheng Shen, Houbao Liu
Frontiers in Oncology.2022;[Epub] CrossRef
A Case Report of Symptom Improvement with Recurrent Gallbladder Cancer Patients Treated with Korean Medicine-based Integrative Cancer Treatment
Eun-ju Ko, Sung-kuk Do, Ji-hye Park, Si-yeon Song, Yeon-weol Lee, Hwa-seung Yoo
The Journal of Internal Korean Medicine.2022; 43(3): 477. CrossRef
Target nursing care on anxiety and depression in patients with gallbladder cancer during perioperative period
Shuang Liu, Li Zhang, Xiu-e Guan, Lei Zhang, Rui Wang
Medicine.2022; 101(31): e29883. CrossRef
Epidemiological trends of gallbladder cancer in Australia between 1982 to 2018: A population-based study utilizing the Australian Cancer Database
Taha Mollah, Marc Chia, Luke C. Wang, Prasenjit Modak, Kirby R. Qin
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 263. CrossRef
A nomogram for predicting cancer-specific survival for elderly patients with gallbladder cancer
Chong Wen, Jie Tang, Tao Wang, Hao Luo
BMC Gastroenterology.2022;[Epub] CrossRef
Incidence and Preoperative Predictor Factors of Gallbladder Cancer Before Laparoscopic Cholecystectomy: a Systematic Review
Tarek Kellil, Mohamed Ali Chaouch, Emna Aloui, Mohamed Amine Tormane, Sahbi Khaled Taieb, Faouzi Noomen, Khadija Zouari
Journal of Gastrointestinal Cancer.2021; 52(1): 68. CrossRef
Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
Hyehyun Jeong, Jae Ho Jeong, Kyu-Pyo Kim, Sang Soo Lee, Dong Wook Oh, Do Hyun Park, Tae Jun Song, Yangsoon Park, Seung-Mo Hong, Baek-Yeol Ryoo, Changhoon Yoo
Cancers.2021; 13(2): 161. CrossRef
Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers
Ismaïl Hendaoui, Ahlem Lahmar, Luca Campo, Sihem Mebarki, Sandrine Bichet, Daniel Hess, Martin Degen, Nidhameddine Kchir, Leila Charrada-Ben Farhat, Rania Hefaiedh, Christian Ruiz, Luigi M. Terracciano, Richard P. Tucker, Lotfi Hendaoui, Ruth Chiquet-Ehri
Frontiers in Immunology.2021;[Epub] CrossRef
An overview on possible links between aflatoxin B1 exposure and gallbladder cancer
Jéssica Costa, Nelson Lima, Cledir Santos
Mycotoxin Research.2021; 37(3): 205. CrossRef
Gender Difference in Gallbladder Cancer: Focusing on the Clinical Characteristics, Treatment, and Prognosis of Korean Patients
Eui Joo Kim
The Korean Journal of Gastroenterology.2021; 78(1): 27. CrossRef
Urban-rural disparity in cancer mortality and changing trend in Tianjin, China, during 1999 and 2016
Wenlong Zheng, Hui Zhang, Dezheng Wang, Chong Wang, Shuang Zhang, Chengfeng Shen, Wei Li, Guohong Jiang
BMC Cancer.2021;[Epub] CrossRef
Spatial epidemiologic analysis of the liver cancer and gallbladder cancer incidence and its determinants in South Korea
Jieun Jang, Dae-Sung Yoo, Byung Chul Chun
BMC Public Health.2021;[Epub] CrossRef
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer
Ji Hye Kim, Kyungbin Kim, Misung Kim, Young Min Kim, Jae Hee Suh, Hee Jeong Cha, Hye Jeong Choi
Journal of Pathology and Translational Medicine.2020; 54(2): 154. CrossRef
Genetic landscape of gallbladder cancer: Global overview
Ravi Mehrotra, Sonam Tulsyan, Showket Hussain, Balraj Mittal, Sundeep Singh Saluja, Sandeep Singh, Pranay Tanwar, Asiya Khan, Milind Javle, Manal M. Hassan, Shubham Pant, Xabier De Aretxabala, Bhawna Sirohi, Preetha Rajaraman, Tanvir Kaur, G.K. Rath
Mutation Research/Reviews in Mutation Research.2018; 778: 61. CrossRef

9,635 View
245 Download
18 Web of Science
21 Crossref

Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis: Se-Il Go, Young Saing Kim, In Gyu Hwang, Eun Young Kim, Sung Yong Oh, Jun Ho Ji, Haa-Na Song, Se Hoon Park, Joon Oh Park, Jung Hun Kang; Cancer Res Treat. 2016;48(4):1274-1285. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.502

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection.
Materials and Methods
Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors.
Results
In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups.
Conclusion
The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.

Citations

Citations to this article as recorded by

Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection
Sundeep Singh Saluja, Phani Kumar Nekarakanti, Pramod Kumar Mishra, Anurita Srivastava, Kishore Singh
Journal of Gastrointestinal Surgery.2022; 26(2): 398. CrossRef
Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
Frontiers in Oncology.2021;[Epub] CrossRef
Current standards and future perspectives in adjuvant treatment for biliary tract cancers
Angela Lamarca, Julien Edeline, Mairéad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle
Cancer Treatment Reviews.2020; 84: 101936. CrossRef
Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer
Jung Ho Im, Woo Jung Lee, Chang Moo Kang, Ho Kyoung Hwang, Jinsil Seong
HPB.2020; 22(8): 1168. CrossRef
Prognostic Factors for Operated Gallbladder Cancer
Bala Basak Oven Ustaalioglu, Ahmet Bilici, Mesut Seker, Umut Kefeli, Dincer Aydin, Serkan Celik, Tarik Demir, Burcak Erkol
Journal of Gastrointestinal Cancer.2019; 50(3): 451. CrossRef
Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer
Abhay K. Kattepur, Shraddha Patkar, Mahesh Goel, Anant Ramaswamy, Vikas Ostwal
Journal of Gastrointestinal Surgery.2019; 23(11): 2232. CrossRef
A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer
Carlos Manterola, Galo Duque, Luis Grande, Xabier de Aretxabala, Roque Conejeros, Tamara Otzen, Nayely García
HPB.2019; 21(11): 1427. CrossRef
Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis
Byoung Hyuck Kim, Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Young Hoon Kim, Dong Wan Seo, Amol K. Narang, Joseph M. Herman
Annals of Surgical Oncology.2018; 25(1): 255. CrossRef
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
T Ebata, S Hirano, M Konishi, K Uesaka, Y Tsuchiya, M Ohtsuka, Y Kaneoka, M Yamamoto, Y Ambo, Y Shimizu, F Ozawa, A Fukutomi, M Ando, Y Nimura, M Nagino, S Nakamori, T Ajiki, H Baba, R Yamaguchi, M Kawai, H Nagano, F Miura, T Arai, Y Nishiwaki, S Kawasaki
British Journal of Surgery.2018; 105(3): 192. CrossRef
Adjuvant systemic therapy and postoperative outcomes after resection of node positive gallbladder cancer
Jiong-Jie Yu, Xin-Fei Xu, Tian Yang
International Journal of Surgery.2018; 54: 307. CrossRef
The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer
Luxi Yin, Qi Xu, Jingjing Li, Qing Wei, Jieer Ying
Medicine.2018; 97(50): e13570. CrossRef
Surgical Management of Gallbladder Cancer
Gyulnara G. Kasumova, Omidreza Tabatabaie, Robert M. Najarian, Mark P. Callery, Sing Chau Ng, Andrea J. Bullock, Robert A. Fisher, Jennifer F. Tseng
Annals of Surgery.2017; 266(4): 625. CrossRef

14,967 View
203 Download
17 Web of Science
12 Crossref

Co-Expression of Cox-2, C-Met and β-catenin in Cells Forming Invasive front of Gallbladder Cancer: Woo Sung Moon, Ho Sung Park, Ho Lee, Rama Pai, Andrzej S. Tarnawski, Kyung Ryoul Kim, Kyu Yun Jang; Cancer Res Treat. 2005;37(3):171-176. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.171

Abstract PDF PubReader ePub

Purpose

Gallbladder cancer is a malignancy with poor prognosis, predominantly resulting from invasion and metastasis. Our previous studies have demonstrated that prostaglandin E₂ (PGE₂), generated by cyclooxygenase 2 (Cox-2), transactivates epidermal growth factor receptor (EGFR), c-Met and β-catenin; thus, enhancing colon cancer cell growth and invasiveness in vitro. To determine whether these findings are applicable to clinical conditions, we examined the expression and cellular localization/co-localization of Cox-2, c-Met, β-catenin, EGFR and c-erbB2 in gallbladder cancer.

Materials and Methods

Thirty-five specimens of invasive gallbladder cancer, 8 in situ carcinoma and 7 adenoma specimens were immunostained with specific antibodies against Cox-2, c-Met, β-catenin, EGFR and c-erbB2. The cellular distribution, localization and colocalization were examined, and the signal intensities quantified in: a) the central area of gallbladder cancer and b) cancer cells forming the invasive front.

Results

Cox-2, c-Met, β-catenin, c-erbB2 and EGFR were over-expressed in 80, 74, 71, 62 and 11% of invasive gallbladder cancers, respectively. β-catenin was expressed in 80% of non-malignant specimens, exclusively in the cell membrane, while the cancer specimens showed cytoplasmic and/or nuclear staining. Significantly higher Cox-2, c-Met and β-catenin expressions were present in cancer cells of the invasive front than in the tumor central areas (p<0.001), and these expressions were significantly (p=0.01) associated with the invasion depth. Co-expressions of Cox-2, c-Met, β-catenin and c-erbB2 were present in 42% of the specimens in cancer cells forming the invasive front.

Conclusion

The overexpressions, and often co-localizations, of Cox-2, c-Met and β-catenin in cancer cells forming the invasive front indicate their local interactions and important roles in invasion.

Citations

Citations to this article as recorded by

EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance
Yeseul Kim, Seungyun Jee, Hyunsung Kim, Seung Sam Paik, Dongho Choi, Su Hyun Yoo, Su-Jin Shin
The Oncologist.2024; 29(8): e1051. CrossRef
Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
Molecular and Cellular Biochemistry.2024;[Epub] CrossRef
Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer
Kamini Yadav, Preeti Agarwal, Madhu Kumar, Sameer Gupta, Medha Mishra, Malti Kumari Maurya, Sumaira Qayoom, Madhu Mati Goel
Indian Journal of Pathology and Microbiology.2023; 66(1): 44. CrossRef
Krukenberg Tumor Related to Gallbladder Cancer in a Young Woman: A Case Report and Review of the Literature
Giulia Grizzi, Michele Ghidini, Margherita Ratti, Marianna D’Ercole, Giulia Tanzi, Annalisa Abbiati, Andrea Celotti, Daniele Spada, Gian Luca Baiocchi, Maria Bonomi
Journal of Personalized Medicine.2023; 13(6): 957. CrossRef
Design, synthesis and evaluation of 4,7-disubstituted 8-methoxyquinazoline derivatives as potential cytotoxic agents targeting β-catenin/TCF4 signaling pathway
Kaushik Neogi, Prashant R. Murumkar, Priyanshu Sharma, Poonam Yadav, Mallika Tewari, Devarajan Karunagaran, Prasanta Kumar Nayak, Mange Ram Yadav
Translational Oncology.2022; 19: 101395. CrossRef
Transcription factor 4 expression and correlation with tumor progression in gallbladder cancer
Kaushik Neogi, Mallika Tewari, Ashish Kumar Singh, Kavyanjali Sharma, Gullanki Naga Venkata Charan Tej, Sumit Singh Verma, Subash Chandra Gupta, Prasanta Kumar Nayak
Journal of Cancer Research and Therapeutics.2022; 18(3): 668. CrossRef
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Niklas Sturm, Jasmin Selina Schuhbaur, Felix Hüttner, Lukas Perkhofer, Thomas Jens Ettrich
Cancers.2022; 14(22): 5580. CrossRef
Knockdown of SLC39A4 Expression Inhibits the Proliferation and Motility of Gallbladder Cancer Cells and Tumor Formation in Nude Mice
Min Li, Kun Fan, Bohao Zheng, David Zekria, Tao Suo, Han Liu, Sheng Shen, Houbao Liu, Xiaoling Ni
Cancer Management and Research.2021; Volume 13: 2235. CrossRef
Aspirin and Statin Use and the Risk of Gallbladder Cancer
Kritika Prasai, Sri Harsha Tella, Siddhartha Yadav, Anuhya Kommalapati, Kristin Mara, Mohamed Mady, Mohamed A. Hassan, Nicha Wongjarupong, Natalia Rodriguez-Payan, Mitesh Borad, Tushar Patel, Lewis R. Roberts, Amit Mahipal
Cancers.2021; 13(5): 1186. CrossRef
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, Paola Ulivi, Francesco Giulio Sullo, Giulia Bartolini, Elisa Tiberi, Giovanni Luca Frassineti
Cancers.2021; 13(22): 5671. CrossRef
UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer
Jianhua Yu, Lawrence Shi, Weiguo Lin, Baochun Lu, Yunfeng Zhao
Biochemical Pharmacology.2020; 172: 113745. CrossRef
Prevalence and Clinicopathological Significance of MET Overexpression and Gene Amplification in Patients with Gallbladder Carcinoma
Yeseul Kim, Seong Sik Bang, Seungyun Jee, Sungeon Park, Su-Jin Shin, Kiseok Jang
Cancer Research and Treatment.2020; 52(2): 481. CrossRef
Genetic mutational analysis of β-catenin gene affecting GSK-3β phosphorylation plays a role in gallbladder carcinogenesis: Results from a case control study
Ruhi Dixit, Manoj Pandey, Sunil Kumar Tripathi, Amit Nandan Dhar Dwivedi, Vijay Kumar Shukla
Cancer Treatment and Research Communications.2020; 23: 100173. CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub] CrossRef
Targeting Lipid Peroxidation for Cancer Treatment
Sofia M. Clemente, Oscar H. Martínez-Costa, Maria Monsalve, Alejandro K. Samhan-Arias
Molecules.2020; 25(21): 5144. CrossRef
β-Catenin expression is associated with cell invasiveness in pancreatic cancer
Jin Niang Nan, Ok Ran Kim, Myung Ah Lee
The Korean Journal of Internal Medicine.2019; 34(3): 618. CrossRef
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks
Sunwang Xu, Ming Zhan, Jian Wang
Cell Death Discovery.2017;[Epub] CrossRef
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle, Angela Lamarca, Lipika Goyal, Jorge Barriuso, Andrew X. Zhu
Cancer Discovery.2017; 7(9): 943. CrossRef
Molecular genetics and targeted therapeutics in biliary tract carcinoma
Eric I Marks
World Journal of Gastroenterology.2016; 22(4): 1335. CrossRef
CIZ1 promoted the growth and migration of gallbladder cancer cells
Dexiang Zhang, Yueqi Wang, Yuedi Dai, Jiwen Wang, Tao Suo, Hongtao Pan, Han Liu, Sheng Shen, Houbao Liu
Tumor Biology.2015; 36(4): 2583. CrossRef
Prognostic significance of COX-2 and β-catenin in colorectal carcinoma
Amani Kazem, Khaled El Sayed, Yasser El Kerm
Alexandria Journal of Medicine.2014; 50(3): 211. CrossRef
A genetic model for gallbladder carcinogenesis and its dissemination
S.G. Barreto, A. Dutt, A. Chaudhary
Annals of Oncology.2014; 25(6): 1086. CrossRef
The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
Takamitsu Sasaki, Kuniyasu Hiroki, Yuichi Yamashita
BioMed Research International.2013; 2013: 1. CrossRef
Significance of epithelial growth factor in the epithelial–mesenchymal transition of human gallbladder cancer cells
Takamitsu Sasaki, Hiroki Kuniyasu, Yi Luo, Daisuke Kato, Satoshi Shinya, Kiyomu Fujii, Hitoshi Ohmori, Yuichi Yamashita
Cancer Science.2012; 103(6): 1165. CrossRef
E-cadherin and c-Met expression in actinic cheilits and lip squamous cell carcinoma
A. Martínez, M.L. Spencer, J. Borlando, M. Flores, I.G. Rojas
Revista Clínica de Periodoncia, Implantología y Rehabilitación Oral.2011; 4(3): 122. CrossRef

10,385 View
63 Download
25 Crossref

First
Prev
Page of 1
Next
Last

Search